A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Stewart Jones, Guillaume B E ^a   Thomas, Paul V ^a   Chen, Man ^a   Druz, Aliaksandr ^a   Joyce, M Gordon ^a   Kong, Wing Pui ^a   Sastry, Mallika ^a   Soto, Cinque ^a   Yang, Yongping ^a   Zhang, Baoshan ^a   Chen, Lei ^a   Chuang, Gwo Yu ^a   Georgiev, Ivelin S ^a   McLellan, Jason S ^a,b   Srivatsan, Sanjay ^a   Zhou, Tongqing ^a   Baxa, Ulrich ^c   Mascola, John R ^a   Graham, Barney S ^a   Kwong, Peter D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; FUSION F GLYCOPROTEIN; GLYCOPROTEIN; MONOMER; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; CAV1 PROTEIN, MOUSE; CAVEOLIN 1; FIBRITIN PROTEIN, ENTEROBACTERIA PHAGE T4; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRAL PROTEIN; VIRUS ANTIGEN; VIRUS FUSION PROTEIN;

ARTICLE; BACTERIOPHAGE; CARBOXY TERMINAL SEQUENCE; DISSOCIATION; DISULFIDE BOND; DRUG STABILITY; DRUG STRUCTURE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOGENICITY; MODEL; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN STABILITY; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; CHEMISTRY; ENTEROBACTERIA PHAGE T4; GENETICS; IMMUNIZATION; IMMUNOLOGY; MOUSE;

MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; BACTERIOPHAGE T4; CAVEOLIN 1; CELL LINE; CYSTEINE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, SUBUNIT; VIRAL FUSION PROTEINS; VIRAL PROTEINS;

EID: 84939155883     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128779     Document Type: Article

References (45)

1. Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infectious disorders drug targets. 2012; 12(2):92-7. Epub 2012/02/18. PMID: 22335498.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 380(9859):2095-128. Epub 2012/12/19. doi:10.1016/s0140-6736(12)61728-0 PMID: 23245604.
3. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and metaanalysis. Lancet. 2010; 375(9725):1545-55. Epub 2010/04/20. doi:10.1016/S0140-6736(10)60206-1 PMID: 20399493; PubMed Central PMCID: PMC2864404.
4. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013; 31 Suppl 2:B209-15. Epub 2013/04/26. doi:10.1016/j.vaccine.2012.11.106 PMID: 23598484; PubMed Central PMCID: PMC3919153.
5. Hurwitz JL. Respiratory syncytial virus vaccine development. Expert review of vaccines. 2011; 10 (10):1415-33. Epub 2011/10/13. doi:10.1586/erv.11.120 PMID: 21988307; PubMed Central PMCID: PMC3255794.
6. Chang J. Current progress on development of respiratory syncytial virus vaccine. BMB reports. 2011; 44(4):232-7. Epub 2011/04/29. doi:10.5483/BMBRep.2011.44.4.232 PMID: 21524347.
7. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102(3):531-7. doi:10.1542/peds.102.3.531 PMID: 9738173.
8. Homaira N, Rawlinson W, Snelling TL, Jaffe A. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. International journal of pediatrics. 2014; 2014:571609. Epub 2014/12/31. doi:10.1155/2014/571609 PMID: 25548575; PubMed Central PMCID: PMC4274815.
9. McDonald TP, Sugrue RJ. The use of two-dimensional SDS-PAGE to analyze the glycan heterogeneity of the respiratory syncytial virus fusion protein. Methods Mol Biol. 2007; 379:97-108. Epub 2007/05/16. doi:10.1007/978-1-59745-393-6-7 PMID: 17502673.
10. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340(6136):1113-7. Epub 2013/04/27. doi:10.1126/science.1234914 PMID: 23618766.
11. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. Journal of virology. 2011; 85(15):7788-96. Epub 2011/05/27. doi:10.1128/JVI.00555-11 PMID: 21613394; PubMed Central PMCID: PMC3147929.
12. Earp LJ, Delos SE, Park HE, White JM. The many mechanisms of viral membrane fusion proteins. Current topics in microbiology and immunology. 2005; 285:25-66. Epub 2004/12/22. PMID: 15609500.
13. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(23):9619-24. Epub 2011/05/19. doi:10.1073/pnas.1106536108 PMID: 21586636; PubMed Central PMCID: PMC31112.
14. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(27):11133-8. Epub 2013/06/19. doi:10.1073/pnas.1309070110 PMID: 23776214; PubMed Central PMCID: PMC3703984.
15. Spits H, Beaumont T, Inventors; MedImmune Limited, assignee. RSV-specific binding molecules and means for producing them. USA2010.
16. Beaumont T, Bakker AQ, Yasuda E. InventorsRSV specific binding molecule 2012.
17. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013; 501(7467):439-43. Epub 2013/08/21. doi:10.1038/nature12442 PMID: 23955151.
18. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013; 342(6158):592-8. Epub 2013/11/02. doi:10.1126/science.1243283 PMID: 24179220.
19. Tao Y, Strelkov SV, Mesyanzhinov VV, Rossmann MG. Structure of bacteriophage T4 fibritin: A segmented coiled coil and the role of the C-terminal domain. Structure. 1997; 5(6):789-98. Epub 1997/06/15. PMID: 9261070.
20. Frank S, Kammerer RA, Mechling D, Schulthess T, Landwehr R, Bann J, et al. Stabilization of short collagen- like triple helices by protein engineering. Journal of molecular biology. 2001; 308(5):1081-9. doi:10.1006/jmbi.2001.4644 PMID: 11352592.
21. Guthe S, Kapinos L, Moglich A, Meier S, Grzesiek S, Kiefhaber T. Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin. Journal of molecular biology. 2004; 337(4):905-15. Epub 2004/03/23. doi:10.1016/j.jmb.2004.02.020 PMID: 15033360.
22. Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. The Journal of experimental medicine. 2010; 207(9):2003-17. Epub 2010/08/04. doi:10.1084/jem.20100025 PMID: 20679401; PubMed Central PMCID: PMC2931166.
23. Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. Journal of virology. 2010; 84(7):3270-9. Epub 2010/01/08. doi:10.1128/JVI.02252-09 PMID: 20053749; PubMed Central PMCID: PMC2838122.
24. Forsell MN, Dey B, Morner A, Svehla K, O'Dell S, Hogerkorp CM, et al. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLOS pathogens. 2008; 4(10):e1000171. Epub 2008/10/04. doi:10.1371/journal.ppat.1000171 PMID: 18833294; PubMed Central PMCID: PMC2542413.
25. Du SX, Idiart RJ, Mariano EB, Chen H, Jiang P, Xu L, et al. Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. Virology. 2009; 395(1):33-44. Epub 2009/10/10. doi:10.1016/j.virol.2009.07.042 PMID: 19815247; PubMed Central PMCID: PMC2801758.
26. Kovacs JM, Noeldeke E, Ha HJ, Peng H, Rits-Volloch S, Harrison SC, et al. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(52):18542-7. Epub 2014/12/17. doi:10.1073/pnas.1422269112 PMID: 25512514; PubMed Central PMCID: PMC4284565.
27. Chakrabarti BK, Feng Y, Sharma SK, McKee K, Karlsson Hedestam GB, Labranche CC, et al. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. Journal of virology. 2013; 87(24):13239-51. Epub 2013/09/27. doi:10.1128/JVI.01247-13 PMID: 24067980; PubMed Central PMCID: PMC3838230.
28. Du L, Leung VH, Zhang X, Zhou J, Chen M, He W, et al. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLOS ONE. 2011; 6(1):e16555. Epub 2011/02/10. doi:10.1371/journal.pone.0016555 PMID: 21304591; PubMed Central PMCID: PMC3029370.
29. Eggink D, Goff PH, Palese P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. Journal of virology. 2014; 88(1):699-704. Epub 2013/10/25. doi:10.1128/JVI.02608-13 PMID: 24155380; PubMed Central PMCID: PMC3911724.
30. Sliepen K, vanMontfort T, Melchers M, Isik G, Sanders RW. Immunosilencing a highly immunogenic protein trimerization domain. The Journal of biological chemistry. 2015. Epub 2015/01/31. doi:10.1074/jbc.M114.620534 PMID: 25635058.
31. Eckert DM, Malashkevich VN, Kim PS. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. Journal of molecular biology. 1998; 284(4):859-65. doi:10.1006/jmbi.1998.2214 PMID: 9837709.
32. Grigoryan G, Keating AE. Structural specificity in coiled-coil interactions. Current opinion in structural biology. 2008; 18(4):477-83. Epub 2008/06/17. doi:10.1016/j.sbi.2008.04.008 PMID: 18555680; PubMed Central PMCID: PMC2567808.
33. Citartan M, Gopinath SC, Tominaga J, Tang TH. Label-free methods of reporting biomolecular interactions by optical biosensors. The Analyst. 2013; 138(13):3576-92. doi:10.1039/c3an36828a PMID: 23646346.
34. VanVliet K, Mohamed MR, Zhang L, Villa NY, Werden SJ, Liu J, et al. Poxvirus proteomics and virushost protein interactions. Microbiology and molecular biology reviews: MMBR. 2009; 73(4):730-49. doi:10.1128/MMBR.00026-09 PMID: 19946139; PubMed Central PMCID: PMC2786582.
35. Heymann JB, Belnap DM. Bsoft: Image processing and molecular modeling for electron microscopy. Journal of structural biology. 2007; 157(1):3-18. Epub 2006/10/03. doi:10.1016/j.jsb.2006.06.006 PMID: 17011211.
36. Ludtke SJ, Baldwin PR, Chiu W. EMAN: Semiautomated software for high-resolution single-particle reconstructions. Journal of structural biology. 1999; 128(1):82-97. Epub 1999/12/22. doi:10.1006/jsbi.1999.4174 PMID: 10600563.
37. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol. 1988; 26(2):153-62. Epub 1988/10/01. PMID: 3183639.
38. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology. 2012; 434 (1):129-36. Epub 2012/10/16. doi:10.1016/j.virol.2012.09.022 PMID: 23062737; PubMed Central PMCID: PMC3492879.
39. Swanson KA, Balabanis K, Xie Y, Aggarwal Y, Palomo C, Mas V, et al. A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes. Journal of virology. 2014; 88(20):11802-10. Epub 2014/08/01. doi:10.1128/JVI.01225-14 PMID: 25078705; PubMed Central PMCID: PMC4178725.
40. Grigoryan G, Degrado WF. Probing designability via a generalized model of helical bundle geometry. Journal of molecular biology. 2011; 405(4):1079-100. Epub 2010/10/12. doi:10.1016/j.jmb.2010.08.058 PMID: 20932976; PubMed Central PMCID: PMC3052747.
41. Zokarkar A, Connolly SA, Jardetzky TS, Lamb RA. Reversible inhibition of fusion activity of a paramyxovirus fusion protein by an engineered disulfide bond in the membrane-proximal external region. Journal of virology. 2012; 86(22):12397-401. Epub 2012/09/07. doi:10.1128/JVI.02006-12 PMID: 22951841; PubMed Central PMCID: PMC3486459.
42. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109 (8):3089-94. Epub 2012/02/11. doi:10.1073/pnas.1115941109 PMID: 22323598; PubMed Central PMCID: PMC3286924.
43. Oshaben KM, Salari R, McCaslin DR, Chong LT, Horne WS. The native GCN4 leucine-zipper domain does not uniquely specify a dimeric oligomerization state. Biochemistry. 2012; 51(47):9581-91. Epub 2012/11/03doi:10.1021/bi301132k PMID: 23116373; PubMed Central PMCID: PMC3535301.
44. Mason JM, Muller KM, Arndt KM. Considerations in the design and optimization of coiled coil structures. Methods Mol Biol. 2007; 352:35-70. Epub 2006/10/17. doi:10.1385/1-59745-187-8:35 PMID: 17041258.
45. Dames SA, Kammerer RA, Wiltscheck R, Engel J, Alexandrescu AT. NMR structure of a parallel homotrimeric coiled coil. Nature structural biology. 1998; 5(8):687-91. Epub 1998/08/12. doi:10.1038/1382 PMID: 9699631.